S-1

ILUS Completes Acquisition and Provides Dividend, Merger and Subsidiary Update

Retrieved on: 
Friday, December 29, 2023
Replay Solutions, Sale, Acquisition, Emergency, S-1, Mining, ERT, Exchange, Growth, Mergers and acquisitions, OTC, Security (finance), Shareholder Meeting

An update is provided on several matters of importance for Shareholders including the acquisition, an associated dividend for ILUS Shareholders, merger agreement negotiations, subsidiaries, and financing.

Key Points: 
  • An update is provided on several matters of importance for Shareholders including the acquisition, an associated dividend for ILUS Shareholders, merger agreement negotiations, subsidiaries, and financing.
  • Following ERT’s acquisition of Emergency Response assets from ILUS, it intends to pay a special equity dividend to ILUS Shareholders and ERT has appointed its own legal counsel with whom it is finalizing the matter.
  • The structure of the dividend is such that following its intended payment to ILUS Shareholders, ILUS will retain its controlling interest in ERT.
  • Having been approached, the ILUS management team is currently in discussions regarding a merger with a NASDAQ listed company.

TKO Announces Secondary Offering of 8,400,000 Shares of Class A Common Stock by a Selling Stockholder

Retrieved on: 
Thursday, November 9, 2023
Sports, Other Entertainment, Entertainment, Martial Arts, Wrestling, Sale, NYSE, EDGAR, Security (finance), TKO, Form, Common stock, Varick Street, 2nd Floor, Morgan Stanley, Prospectus, S-1, Common, Part Two

The Selling Stockholder will receive all of the net proceeds from this offering.

Key Points: 
  • The Selling Stockholder will receive all of the net proceeds from this offering.
  • A shelf registration statement on Form S-1 (including a prospectus) relating to the offering of Class A Common Stock has been declared effective by the Securities and Exchange Commission.
  • The offering will be made only by means of a prospectus supplement and an accompanying prospectus.
  • All statements in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the proposed underwritten secondary offering of shares of Class A Common Stock.

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
PDAC, Camrelizumab, FGFR, Abstract, Indian Institutes of Technology, IIT, AACR, Combo, CRC, S-1, DCR, MSS, OS, Mutation, Oncology, NSCLC, Cholangiocarcinoma, Lung cancer, PFS, ASCO, Sintilimab, HKEX, Phase 4, Endometrial cancer, Publication, American Society of Clinical Oncology, Patient, IHCC, Irinotecan, Annual general meeting, GM-CSF, European Society for Medical Oncology, PD-1, FGFR2, Safety, Phenotype, Society, Thyroid cancer, ORR, Pharmaceutical industry, Medical device

13 presentations and publications, including several investigator-initiated-trials (“IITs”), are listed in the table below.

Key Points: 
  • 13 presentations and publications, including several investigator-initiated-trials (“IITs”), are listed in the table below.
  • These new analyses add to the understanding of fruquintinib efficacy by specific lines of therapy as well as adverse events of special interest (“AESI”).
  • Median PFS was not reached when results from this study were initially presented at the 2021 Chinese Society of Clinical Oncology Annual Meeting (data cut-off on August 31, 2021).
  • Preclinical data presented at the American Association for Cancer Research Annual Meeting 2023 (AACR 2023) showed that it has strong activity against FGFR-deregulated tumors, supporting investigation in patients with FGFR alterations (such as fusion and mutation) either as a single agent or in combination with PD-1 blockade.

Tivic Health and Reliefband Technologies, LLC Terminate Acquisition Agreement

Retrieved on: 
Friday, December 9, 2022
General Health, Public Relations, Investor Relations, Health, Communications, Health Technology, Partnership, Registration statement, Annual report, System, COVID-19, S-1, Inflammation, Acquisition, Risk management

Tivic Health Systems, Inc. (Tivic) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that Tivic Health and Reliefband Technologies, LLC have, by mutual agreement, terminated the parties agreement for the acquisition of the Reliefband product line and related assets entered into on October 7, 2022.

Key Points: 
  • Tivic Health Systems, Inc. (Tivic) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced that Tivic Health and Reliefband Technologies, LLC have, by mutual agreement, terminated the parties agreement for the acquisition of the Reliefband product line and related assets entered into on October 7, 2022.
  • The relationship between Tivic Health and Reliefband management remains on good terms despite both teams disappointment in the outcome.
  • Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers with a choice in the treatment of inflammation and certain other related conditions.
  • Forward-looking statements are based on Tivic Health Systems, Inc.s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.

Tivic Health Signs Agreement with ALOM to Manage Product Supply Chain, Assembly, and Logistics

Retrieved on: 
Thursday, December 1, 2022
Biotechnology, Pharmaceutical, Health, Packaging, Health Technology, Logistics, Supply Chain Management, Transport, Manufacturing, COVID-19, Growth, National Association of Manufacturers, MSRP, System, History, Organization, National Association, The, Partnership, Sabia, NAM, Government, Data management, Annual report, Inflammation, Fortune 500, New Year, S-1, Registration statement, FDA, 3D printing, Risk management

Tivic Health Systems, Inc. (Tivic) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has hired ALOM Technologies Corporation (ALOM), a leader in global supply chain product and service delivery programs, to manage product supply chain, assembly, and logistics.

Key Points: 
  • Tivic Health Systems, Inc. (Tivic) (Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced it has hired ALOM Technologies Corporation (ALOM), a leader in global supply chain product and service delivery programs, to manage product supply chain, assembly, and logistics.
  • Headquartered in the U.S., ALOM will be the companys 3rd party logistics (3PL) warehouse, fulfillment, and production partner responsible for storing, packaging, and shipping Tivic product orders.
  • Operating out of 19 global locations, ALOMs technology-driven supply chain offerings include inventory management, contract manufacturing, procurement, fulfillment, warehouse operations, and logistics systems technology.
  • ALOMs relationship with Tivic Health brings together two organizations that share a commitment to improving the quality of peoples lives, said Hannah Kain, president, and CEO, of ALOM.

Tivic Health Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Health Technology, Health, Medical Devices, FDA, Investment, Australian Financial Review, Marketing, Advertising, Insignia Systems, Inc., Three Months Gone, Telephone, Sumathi Best Television Current Reporting Award, Partnership, S-1, IPO, Webcast, CE, Social media, Registration statement, Research, Acquisition, D&O, Security (finance), D, Inflammation, Annual report, Nausea, Nine Months, COVID-19, Pharmaceutical industry, Risk management, Renewable energy, Video game, Online shopping

Tivic Health Systems, Inc. (Tivic Health, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended September 30, 2022.

Key Points: 
  • Tivic Health Systems, Inc. (Tivic Health, Nasdaq: TIVC), a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced its financial results for the quarter ended September 30, 2022.
  • Up to $1.5 million of the acquisition consideration is payable, at the election of Tivic, in restricted shares of Tivics common stock.
  • The company reports a net loss of $2.6 million for Q3 2022, compared to $2.3 million in Q3 2021.
  • Management will host a conference call and webcast on Monday, November 14, 2022, at 1:30 PM PT / 4:30 PM ET to discuss the companys third quarter 2022 financial results and business updates.

Faraday Future Receives Nasdaq Acceptance of Plan to Regain Listing Compliance

Retrieved on: 
Tuesday, March 15, 2022
Engineering, Automotive, Automotive Manufacturing, Manufacturing, Performance & Special Interest, Alternative Vehicles, Fuels, SEC, Nasdaq, Form, Compliance, Sale, S-1, Special, Communication, Forward-looking statement, Private Securities Litigation Reform Act, FF, Risk management

This press release includes forward looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This press release includes forward looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
  • These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
  • Forward-looking statements speak only as of the date they are made.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220315006348/en/

POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022

Retrieved on: 
Tuesday, March 15, 2022
SEC, Molecular imaging, Department, Radiation therapy, GLOBE, Patient, Intention, Private Securities Litigation Reform Act, Actinium-225, Risk, COVID-19, Forward-looking statement, Université Laval, Safety, Assistant, Oncology, MCRPC, Radiation, NASDAQ, Neoplasm, Society of Nuclear Medicine and Molecular Imaging, Radiology, Company, Research, Cancer, SNMMI, Johns Hopkins Hospital, Nuclear medicine, Toxicity, Prostate cancer, SPLASH, Phase, Radiopharmaceutical, S-1, Terminology, Medical imaging, Dosimetry

INDIANAPOLIS, March 15, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, recently announced publication of the dosimetry results from the lead-in cohort of the Phase III mCRPC SPLASH study. The findings presented by Dr. Jean-Mathieu Beauregard concluded that “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied.”

Key Points: 
  • To highlight the importance of dosimetry in radiopharmaceuticals, POINT will be hosting a free investor education event titled Introduction to Dosimetry for Radiopharmaceuticals on Tuesday, March 29, 2022 at 12:00 pm ET.
  • Dr. Kiess is an Assistant Professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins Hospital.
  • About POINT Biopharma Global Inc.
    POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .

Global Tech Industries Group, Inc. Updates Shareholders on Highlights of Last Twelve Months’ Activities

Retrieved on: 
Friday, January 7, 2022
Register, Environmental Defense v. Duke Energy Corp., S-1, Growth, Mining, Company, Pablo Picasso, U.S. Securities and Exchange Commission, Income, Algorithm, App Store (iOS/iPadOS), SEC, Registration statement, Eye, Iron, Student, Partnership, LLC, OTCQB, Diagnosis, GLOBE, Risk, Carnegie Mellon University, Collection, Cryptocurrency, Security (finance), Risk management

The analyzed results provide educators a useful tool in understanding students' areas of interests and needs.

Key Points: 
  • The analyzed results provide educators a useful tool in understanding students' areas of interests and needs.
  • The date of the proposed distribution will determined as soon as practicable when and if the Registration Statement is declared effective.
  • We picked the right people for the jobs, and the Company and its shareholders saw much improvement in 2021.
  • About Global Tech Industries Group, Inc.: GTII, a publicly traded Company incorporated in the state of Nevada, specializing in the pursuit of acquiring new and innovative technologies.

Douglas Elliman Registration Statement Declared Effective

Retrieved on: 
Thursday, December 16, 2021
Tobacco, Retail, Professional Services, Finance, Weather, Phrase, Instagram, Forward-looking statement, U.S. Securities and Exchange Commission, LinkedIn, Form, Tax, Elliman, TikTok, Pandemic, Oliver Cromwell, NYSE, Sale, S-1, Social media, Tax Cuts and Jobs Act of 2017, Public expenditure, Group, COVID-19, Vector Group, Jefferies Group, Risk, Terrorism, SEC, LLC, Sullivan & Cromwell, New Valley LLC, Climate change, Douglas Elliman, Legislation, VGR, YouTube, Twitter, CUSIP, Security (finance), Facebook

Vector Group Ltd. (NYSE: VGR) (Vector Group) today announced that the registration statement on Form S-1 filed by Douglas Elliman Inc. (Douglas Elliman) in connection with its spin-off from Vector Group has been declared effective by the U.S. Securities and Exchange Commission.

Key Points: 
  • Vector Group Ltd. (NYSE: VGR) (Vector Group) today announced that the registration statement on Form S-1 filed by Douglas Elliman Inc. (Douglas Elliman) in connection with its spin-off from Vector Group has been declared effective by the U.S. Securities and Exchange Commission.
  • No action or payment is required by Vector Group stockholders to receive shares of Douglas Elliman.
  • Beginning on December 17, 2021, the new Douglas Elliman common stock is expected to begin trading on a when-issued basis on the NYSE under the symbol DOUG WI and under Douglas Elliman Inc..
  • Vector Group is a holding company for Liggett Group LLC, Vector Tobacco Inc., New Valley LLC, and Douglas Elliman Realty, LLC.